<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104907</url>
  </required_header>
  <id_info>
    <org_study_id>H-17000714-2</org_study_id>
    <nct_id>NCT03104907</nct_id>
  </id_info>
  <brief_title>Prostatic Artery Embolization for Obstructive Uropathy Due to Locally Advanced Prostate Cancer</brief_title>
  <official_title>Prostatic Artery Embolization for Obstructive Uropathy Due to Locally Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the safety and efficacy of prostatic artery
      embolization of patients with recurrent symptoms secondary to locally advanced prostatic
      cancer including pelvic pain, bleeding or need for permanent urinary catheter who are unfit
      for or refuse surgical treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study investigating the safety and efficacy of PAE for patients with
      prostate cancer who suffers from acute urinary retention, severe LUTS and/or recurrent
      complications such as haematuria.

      Our hypothesis is that PAE will eliminate the need for indwelling catheter and improve IPSS
      and QoL 12 months post-procedure.

      1, 3, 6, 9 and 12 months follow-up.

      Main outcome Ability to void after removal of indwelling catheter

      Secondary outcomes DAN-PSS International Prostate Symptom Score (IPSS) Quality of Life (QoL)
      International Index of Erectile Function (IIEF) Prostate volume Peak void flow (Qmax)
      Post-void residual (PVR) Classify complications according to Society of Interventional
      Radiology (SIR) guidelines for reporting Prostate-specific antigen (PSA)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to void spontaneously</measure>
    <time_frame>1 months</time_frame>
    <description>The ability to void after removal of the indwelling catheter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IPSS</measure>
    <time_frame>1, 3, 6, 9, 12 months</time_frame>
    <description>International Prostate Symptom Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>1, 3, 6, 9, 12 months</time_frame>
    <description>Quality of Life (scale and EQ-5D-5L questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF</measure>
    <time_frame>1, 3, 6, 12 months</time_frame>
    <description>International Index of Erectile Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PV</measure>
    <time_frame>1, 6, 12 months</time_frame>
    <description>Prostate Volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PVR</measure>
    <time_frame>1, 6, 12 months</time_frame>
    <description>Post-void residual</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qmax</measure>
    <time_frame>1, 6, 12 months</time_frame>
    <description>Peak void flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA</measure>
    <time_frame>1, 6, 12 months</time_frame>
    <description>Prostate-specific antigen</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Urological Manifestations</condition>
  <condition>Prostatic Diseases</condition>
  <arm_group>
    <arm_group_label>Prostatic Artery Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prostatic Artery Embolization</intervention_name>
    <description>The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.</description>
    <arm_group_label>Prostatic Artery Embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indwelling catheter secondary to locally advanced prostate cancer (PCa) or

          -  Moderate-severe Obstructive LUTS secondary to PCa

          -  Unsuitable for or refuse surgery

        Exclusion Criteria:

          -  Bladder dysfunction(and known neurological conditions affecting bladder function)

          -  Urethral strictures

          -  Bladder neck contracture

          -  Known sphincter anomalies

          -  Big bladder diverticulum or stones

          -  Kidney insufficiency (eGFR &lt; 45)

          -  Coagulation disturbances

          -  Severe atheromatous or tortuosity of arteries

          -  Allergy to contrast medium

          -  Unable to undergo MR imaging

          -  Bladder malignancy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars LÃ¶nn, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Radiologisk Klinik, Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Malling, MD</last_name>
    <phone>004535453024</phone>
    <email>brian.malling.01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Malling, MD</last_name>
      <phone>004535453024</phone>
      <email>brian.malling.01@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Brian Malling</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>IPSS</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>DAN-PSS</keyword>
  <keyword>Complications</keyword>
  <keyword>Prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
    <mesh_term>Urological Manifestations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

